United Kingdom

UK Supreme Court awards Professor Shanks £2m compensation for invention of ‘outstanding benefit’ after 13 year court battle

Rafi Allos

In Shanks v Unilever Plc and others, the UK Supreme Court has, for the first time, handed down a decision on employee compensation for patented inventions. The Supreme Court overturned the previous decisions in the case and decided that Professor Shanks, an employee of Unilever’s UK research subsidiary, CRL, had made a patented invention that Read More

NICE consults on draft guideline on prescribing medicinal cannabis

Matthew Townsend

On 8 August 2019, the National Institute for Health and Care Excellence (NICE) published a draft guideline on prescribing cannabis-based medicinal products (the Draft Guideline) for consultation. The Draft Guideline, which, when finalised, will replace interim clinical guidance issued by specialist medical societies, makes recommendations regarding prescribing cannabis-based medicines for people with intractable nausea and Read More

The cannabis market: helping investors navigate the UK regulatory regime

Matthew Townsend

Last year the global legal cannabis market was estimated to be worth USD12 billion but it is tipped to rise to over USD166 billion by 2025. Liberalisation of the legal framework for cannabis is a significant driver for this growth. Since 1 November 2018, the UK has joined the ranks of over 30 countries legalising Read More

UK High Court orders pre-action delivery up of samples for infringement testing and considers use in other jurisdictions

Rafi Allos

In Boehringer Ingelheim v Generics,* the English High Court ordered the rarely-used remedy of pre-action inspection of property, for the purpose of allowing experiments needed to assess patent infringement. The case provides a useful reminder of the powers of the Court in this area, as well as providing a reference as to how the Court Read More

MHRA provides further guidance on no-deal Brexit plans

Jacqueline Bore

The MHRA has issued updated guidance on its plans for the regulation of medicines, medical devices and clinical trials in the event that the United Kingdom leaves the European Union on 29 March 2019 without any agreement on its future relationship with the EU and, therefore, without any transitional period. The guidance reflects responses to Read More